A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

March 15, 2028

Study Completion Date

March 15, 2028

Conditions
Essential Thrombocythaemia
Interventions
DRUG

Ropeginterferon alfa-2b (BESREMi®)

Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.

Trial Locations (36)

4020

Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology, Linz

4032

University of Debrecen Clinical Center, Clinic of Internal Medicine, Department of Hematology, Debrecen

6020

Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck

8036

University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology, Graz

10000

University Hospital Kralovske Vinohrady, Clinic of Internal Hematology, Prague

10126

University Hospital City of Health and Science of Turin - Hospital Molinette, Complex Structure of Hematology - U, Turin

11528

General Hospital of Athens Alexandra, Therapeutic Clinic, Department of Therapeutics, Athens

28034

University Hospital Ramon y Cajal, Hematology Service, Madrid

30008

Morales Meseguer University General Hospital, Murcia

30625

Hannover Medical School, Clinic for haematology, haemostaseology, oncology and stem cell transplantation, Hanover

32429

Johannes Wesling Hospital Minden, Department of Oncology and Hematology, Minden

33600

Bordeaux University Hospital, Haut-Leveque Hospital, Pessac

40138

Polyclinic S. Orsola-Malpighi, Bologna

50134

Careggi University Hospital, Department of Hematology, Florence

52074

University Hospital Aachen, Clinic of Oncology, Hematology and Stem Cell Transplantation (Medical Clinic IV), Aachen

68167

University Hospital Mannheim, Medical Clinic III, Hematology and Internistic Oncology, Mannheim

75010

Saint-Louis Hospital, Department of Adult Hematology, Paris

86000

Centre Hospitalier Universitaire De Poitiers, Poitiers

89081

University Hospital Ulm, Center for Internal Medicine, Clinic of Internal Medicine III, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm

400015

"Prof. Dr. Ion Chiricuta Institute of Oncology, Hematology Department", Cluj-Napoca

500052

Onco Card Srl, Brasov

700483

Iasi Regional Institute of Oncology, Department of Hematology, Iași

Unknown

Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology, Vienna

625 00

University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno

06120

University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology, Halle

PC 12462

"University General Hospital Attikon", Athens

H-1088

Semmelweis University, Department of Internal Medicine and Haematology, Division of Hematology, Budapest

00161

Umberto I Polyclinic of Rome, Rome

00168

"University Polyclinic Foundation Agostino Gemelli - IRCCS, Service of Hematology", Rome

80-952

University Teaching Centre, Hematology and Transplantology Clinic, Gdansk

40-519

Pratia Oncology Katowice, Katowice

31-501

Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Krakow

93-513

Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, Department of Hematooncology with Subdivision of Daytime Chemotherapy, Lodz

022328

Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation, Crişan

08916

University Hospital Germans Trias i Pujol, Badalona

08036

Hospital Clinic of Barcelona, Department of Hematology, Barcelona

Sponsors
All Listed Sponsors
lead

AOP Orphan Pharmaceuticals AG

INDUSTRY

NCT06514807 - A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients | Biotech Hunter | Biotech Hunter